As of my knowledge cutoff in 2021, there were several new HCPCS codes released for COVID-19 treatments. These codes were created to allow healthcare providers and facilities to bill for certain treatments related to COVID-19. Some examples of new HCPCS codes for COVID-19 treatments include:
- Q0239 – Injection, sotrovimab, 500 mg
- M0243 – Injection, casirivimab and imdevimab, 2400 mg
- M0244 – Injection, regdanvimab, 1200 mg
- Q0245 – Injection, tocilizumab, 1 mg
- Q0246 – Injection, sarilumab, 1 mg
These codes may be used to bill for treatments such as monoclonal antibodies, interleukin-6 (IL-6) inhibitors, and other therapies used to treat COVID-19. It’s important to note that the use of these codes and the coverage of these treatments may vary depending on the patient’s specific health insurance plan and other factors, so it’s important to check with the patient’s insurance provider for the most up-to-date information on coverage and billing.